What did SELECT trial show about semaglutide?

Semaglutide lowered cardiovascular events in SELECT

In the prespecified analyses from the SELECT trial, researchers reported that semaglutide reduced major adverse cardiovascular events (MACE) compared with placebo. The trial’s findings are especially notable because the analysis focuses on how much of the cardiovascular benefit was explained by weight loss.

The investigators estimated that only about one-third of the benefit was mediated through weight reduction. That means a substantial portion of the cardiovascular risk reduction appeared to occur through mechanisms independent of weight loss.

This matters because GLP-1 medicines are widely used for weight management, but SELECT is positioned as evidence for cardiovascular prevention in people at elevated risk who meet the trial’s eligibility criteria. The takeaway is that semaglutide’s protective effect is not simply a downstream effect of shrinking body weight.

In addition, multiple articles in the pool reference debate around the interpretation of semaglutide’s independent effects. The key point consistent across the stories is that the analytical conclusion in SELECT hinges on evaluating relationships between cardiovascular outcomes and changes in adiposity measures.

What the results imply

• Semaglutide can reduce serious cardiovascular events versus placebo.
• Weight loss likely contributes, but it does not explain most of the observed benefit.
• The trial’s statistical approach to mediation and adiposity-related effects is central to the conclusion.

While the pool doesn’t provide detailed subgroup results or absolute event-rate numbers, it clearly signals that the cardiovascular benefit is not fully attributable to weight change, strengthening the argument for semaglutide as a broader cardiovascular risk intervention rather than only a weight-loss therapy.